한국어
Quantus

SCISPARC

SPRC · Nasdaq
$5.29+3.12%
2026-09-04 close

SCISPARC last closed at $5.29 (+3.12%) on 2026-09-04. Listed on Nasdaq; price, financials and dividends update daily after market close.

Loading chart…
Close
No active signal.

New high + volume — the real recordrecord · not a prediction

Last 30 sessions
277 picks
Next-day win rate
44.2%
Avg next-day
-0.28%
vs market
-0.51%p

Every new-high-plus-volume pick we actually published (US market) — not this stock alone.

Trade plan

Fill entry, stop, account size and risk percent to get a share count. The stop must sit below the entry.

A calculator · not advice or a guarantee

Financials & valuation at a glance

B-
Overall: 건강관리 413/745 · top 55%
Factor composite · relative position in sector

PER — · PBR 0.24 — own-history percentile 9/100 · 87/100

Open self-history band
PER9/100
PBR87/100

Factual information · not investment advice

Past reported results · not investment advice

More — deeper indicators

Financial safety

Reference indicatorAs of 2024
Distress zoneFinancial-metric reference signal
Altman Z'' zoneZ'' -16.90
Distress
Grey
Safe
The marker shows the current Z'' value within the displayed zones.
Altman Z''
-16.90
Beneish M-Score
23.35

Statistical manipulation-risk signal

Sloan accrual
-11.40%

부실·조작 위험을 나타내는 사실 지표입니다. 투자 조언이 아니며, 검증 전이라 참고용입니다.

Factual information, not investment advice.

Earnings quality · Piotroski F-Score

4/9Moderate

Piotroski measures year-over-year financial improvement, not absolute quality.

Financial improvement score4/9

Profitability

  • Positive ROANot passed
  • Positive OCFNot passed
  • Improving ΔROANot passed
  • Accruals (OCF > net income)Pass

Leverage & liquidity

  • Lower debtPass
  • Higher current ratioPass
  • No new sharesPass

Efficiency

  • Higher gross marginNot passed
  • Higher asset turnoverNot passed

Calculation note: F7(신주)은 equity/asset 유지로 근사

Already-stable companies may score lower when year-over-year improvement is limited.

Factual information, not investment advice.

Forensic signals

Anomaly and structural signals observed in the financial statements.

Revenue qualityDanger

매출 흑자인데 영업CF 적자 (OCF/매출 -391%). 통계적 정황 신호이며 회계부정 단정이 아닙니다.

Margin trendWarning

영업이익률 악화 (-236.7% → -560.2%, -323.5%p). 통계적 정황 신호이며 회계부정 단정이 아닙니다.

Factual information, not investment advice.

Industry structure

USAs of 2026-09-05

건강관리

This stock is in 건강관리: revenue rank 489 of 543, share 0%.

489 / 5430%revenue share

Who dominates this industry?

  1. 1CVS Health14.1%
  2. 2McKesson13.6%
  3. 3Cigna9.4%
  4. 4Cardinal Health8.4%
  5. 5Centene6.2%
  6. 6SCISPARC0%

Concentration

DistributedCR3 37.1%
HHI 642543 revenue members

HHI and CR3 are separate industrial-organization facts; they are not the polarization verdict.

Polarization

Winner-take-all deepeningConsistent

Polarization measures industry gaps and structure, not valuation, forecast, or investment advice.

Margin lens

IQR%p
159.97
Direction
축소
Level
넓음
Years
21

Value lens

P90/P10
24.4
Median P/B
3.02
Level
넓음
n
463

Survivorship note: 현재 산업 멤버십을 과거 연도에 소급 적용 — 과거 진입·퇴출 기업 미반영(복원 불가)

Factual information, not investment advice.

Risk sensitivity — adverse assumptions

Metric changes under stated assumptions; not a forecast or investment advice.

Base metrics

Operating margin
-560.2%
Interest coverage
-243.9x
Return on equity (ROE)
-77.1%

Operating margin −5pp

Operating loss
Interest coverageBase -243.9x adverse case -246x
Return on equity (ROE)Base -77.1% adverse case -90.9%

Revenue −15%

Interest coverage risk
Interest coverageBase -243.9x adverse case -207.3x
Return on equity (ROE)Base -77.1% adverse case -76.6%

Interest rate +2pp

Interest coverage risk
Interest coverageBase -243.9x adverse case -99.1x
Return on equity (ROE)Base -77.1% adverse case -90.6%

Interest coverage limit

Already below the limit by 562.5pp

Interest coverage limit at an operating margin of 2.3%

Interest expense coverage threshold

Connections

AI-extracted related companies · for reference

Customers
Purdue Pharma
🔗 See in the full market map →

Recent filings

Filings for overseas stocks are on the way. For now we cover Korean stocks only.

About SCISPARC
What technical signals does SCISPARC (SPRC) have?
SCISPARC current technical signals: no active technical signal.
Is SCISPARC a cup-and-handle pattern?
No. SCISPARC has no valid cup-and-handle signal right now.
What are SCISPARC's financials and valuation?
SCISPARC's income statement, balance sheet and cash flow are free for the most recent 8 years; the full history is on Pro. PER/PBR, dividend yield and sector valuation bands are free.

Like these rules? Backtest them.

Run this signal on this ticker in the free backtest builder — same window, no install.

Backtest this rule ↗

Quantus Signal · live data · not investment advice · Privacy Policy